A Radio‐Pharmaceutical Fluorescent Probe for Synergistic Cancer Radiotherapy and Ratiometric Imaging of Tumor Reactive Oxygen Species
Angewandte Chemie · 17.07.2023 · 135 (29)
DOI: 10.1002/ange.202305744 ↗Kurz gefasst
Fachartikel in der Zeitschrift Angewandte Chemie, online erschienen am 13.06.2023. Verfasst von Xiaoguang Ge und 6 weiteren Autor:innen. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 60 Literaturangaben. Gefördert von: Fundamental Research Funds for the Central Universities, National Natural Science Foundation of China, Natural Science Foundation of Fujian Province.
Abstract (Originalsprache)
Radiotherapy (RT) is an effective and widely applied cancer treatment strategy in clinic. However, it usually suffers from radioresistance of tumor cells and severs side effects of excessive radiation dose. Therefore, it is highly significant to improve radiotherapeutic performance and monitor real‐time tumor response, achieving precise and safe RT. Herein, an X‐ray responsive radio‐pharmaceutical molecule containing chemical radiosensitizers of diselenide and nitroimidazole (BBT‐IR/Se‐MN) is reported. BBT‐IR/Se‐MN exhibits enhanced radiotherapeutic effect via a multifaceted mechanisms and self‐monitoring ROS levels in tumors during RT. Under X‐ray irradiation, the diselenide produces high levels of ROS, leading to enhanced DNA damage of cancer cell. Afterwards, the nitroimidazole in the molecule inhibits the damaged DNA repair, offering a synergetic radiosensitization effect of cancer. Moreover, the probe shows low and high NIR‐II fluorescence ratios in the absence and presence of ROS, which is suitable for precise and quantitative monitoring of ROS during sensitized RT. The integrated system is successfully applied for radiosensitization and the early prediction of in vitro and in vivo RT efficacy.
Förderung
- Fundamental Research Funds for the Central Universities
- National Natural Science Foundation of China
- Natural Science Foundation of Fujian Province
Zitieren
APA
Ge, X., Su, L., Chen, Z., Zhu, K., Zhang, X., Wu, Y., & Song, J. (2023). A Radio‐Pharmaceutical Fluorescent Probe for Synergistic Cancer Radiotherapy and Ratiometric Imaging of Tumor Reactive Oxygen Species. Angewandte Chemie, 135(29). https://doi.org/10.1002/ange.202305744
Vancouver
Ge X, Su L, Chen Z, Zhu K, Zhang X, Wu Y, et al. A Radio‐Pharmaceutical Fluorescent Probe for Synergistic Cancer Radiotherapy and Ratiometric Imaging of Tumor Reactive Oxygen Species. Angewandte Chemie. 2023;135(29). doi:10.1002/ange.202305744
BibTeX
@article{Ge2023,
author = {Ge, Xiaoguang and Su, Lichao and Chen, Zhongxiang and Zhu, Kang and Zhang, Xuan and Wu, Ying and Song, Jibin},
title = {A Radio‐Pharmaceutical Fluorescent Probe for Synergistic Cancer Radiotherapy and Ratiometric Imaging of Tumor Reactive Oxygen Species},
journal = {Angewandte Chemie},
year = {2023},
volume = {135},
number = {29},
doi = {10.1002/ange.202305744}
}
EUVIMED